Browse articles from EyeWorld.org related to myopia. EyeWorld is the award-winning member publication of ASCRS. The magazine provides news and updates from the Society as well as clinical features in the areas of cataract, refractive, cornea, glaucoma, and practice management. It publishes quarterly with editorial direction from its medical editorial board and staff.
➤ Results from Phase 2a study evaluating glaucoma drop ➤ Enrollment complete for epi-on crosslinking trial ➤ Phase 2 clinical trial begins for investigational dry eye drop ➤ Enrollment complete for Phase 2 study to evaluate diabetic retinopathy treatment ➤ Phase 2b trial for wet AMD treatment begins enrollment ➤ ASCRS news and events
The EVO Visian ICL (STAAR Surgical) was recently approved for the treatment of myopia and astigmatism, with updates to the previous ICL technology. Several physicians discussed the technology with EyeWorld: what’s new, how they’re using the product, and results they’ve seen so far.
➤ Topline results from Phase 3 study of atropine for myopia progression ➤ Phase 3 results for novel glaucoma drop ➤ Positive results from two Phase 3 studies for patients with RVO ➤ Phase 3 results for cell therapy treating macular telangiectasia type 2 ➤ Single injection of investigational compound for DME improves BCVA ➤ FDA accepts BLA for ophthalmic bevacizumab ➤ Mobile phone attachment developed for ophthalmic clinical trials ➤ ASCRS news and events
➤ Autologous stem cell therapy to treat dry AMD ➤ Topline results from Phase 3 trial for GA therapy ➤ Update on Phase 3 myopia progression clinical trial ➤ FDA accepts NDA application for investigational dry eye therapy ➤ ASCRS news and events
➤ Phase 3 trial investigating inflammation, pain management after cataract surgery ➤ Positive topline data in study for RP gene therapy ➤ Study: Intravitreal cancer drug found to preserve vision more than traditional therapy ➤ Several studies show efficacy of home-based OCT ➤ Company announces expense reduction and refocus plan ➤ ASCRS news and events
➤ FDA 510(k) clearance granted to FLACS system ➤ New genetic eye disease discovered ➤ Primary endpoint met in Phase 3 trial for dry eye drug candidate ➤ New analysis of thyroid eye disease therapy ➤ Licensing agreement for commercialization of investigational myopia therapeutic ➤ ASCRS news and events
➤ FDA approves new ICL ➤ Home tonometer receives 510(k) clearance ➤ First patient treated in what will be the largest standalone MIGS clinical trial ➤ Topline results from second Phase 3 trial of mydriasis-reversing drug ➤ ASCRS news and events
➤ FDA clearance for viscodelivery system ➤ FDA approves IND application for immunomodulatory agent for dry eye ➤ Phase 2b results for sustained-release, IOP-lowering implant ➤ Positive topline Phase 2 results for investigational dry eye drug ➤ Phase 2 trials begin for two transdermal drug formulations ➤ Second pivotal trial begins for wet AMD gene therapy ➤ Alcon completes acquisition of Ivantis ➤ ASCRS news and events
➤ Positive topline clinical data for investigational topical presbyopia treatment ➤ FDA grants IDE for modular IOL with fluid-filled optic ➤ First participants enrolled in Phase 3 trial for mydriasis reversal ➤ Analysis: Subgroup of dry eye patients benefit from investigational treatment ➤ NDA approved for generic drug designed to treat inflammation, pain ➤ First patient enrolled in Phase 2a study for wet AMD and DME candidate ➤ ASCRS news and events
➤ Eyecelerator@AAO kicks off ➤ Digital health in ophthalmology ➤ Cornea spotlight ➤ Reimbursement ➤ Focused session on myopia ➤ Eyecelerator closes with awards and ‘eyes on the future’